Capricor Therapeutics

Linda Marban, Ph.D., CEO
Los Angeles, CA
Capricor Therapeutics is a cutting-edge biotech company focused on the discovery and development of novel therapies for the treatment and prevention of diseases. Capricor’s lead product candidate, allogeneic Cardiosphere-Derived Cells (CDCs), known as CAP-1002, is in late-stage clinical development as a treatment for Duchenne muscular dystrophy. In addition, the Company is conducting research and development on its exosomes platform technology for a variety of inflammatory and cardiac indications. In response to the fight against a global pandemic, our team is applying its cell and exosome technologies against COVID-19, including the development of a potential vaccine.

By using this website you agree to accept our Privacy Policy and Terms & Conditions